Clinical trial
Stat3 Signaling Pathway Aberrancies in Pediatric AML
NCT01138332 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Stat3 Signaling Pathway Aberrancies in Pediatric AML
- Lead sponsor
- Children's Oncology Group
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 30, 2009
- Completion date
- March 31, 2010
- Enrollment
- 20 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.